Search Results
Your search for ,foR matches 32446 pages
Showing 14901 - 14950Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers
In a linked Surveillance, Epidemiology, and End Results and Medicare study reported in the Journal of Clinical Oncology, Salz et al found that chronic opioid use varied by cancer among older cancer survivors. By 6 years after diagnosis, survivors were no more likely to be chronic opioid users...
Strategies to Increase Inclusion of Racial and Ethnic Minorities in Clinical Trials
As reported in the Journal of Oncology Practice by Regnante et al, the National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group identified strategies employed by U.S. Cancer Centers of Excellence that have resulted in increased inclusion of racial ...
Use of Specialized PET/CT to Assess Estrogen Receptor Status in Recurrent or Metastatic Breast Cancer
In a Korean study reported in The Lancet Oncology, Chae et al found that 16α-[18F]fluoro-17β-oestradiol (18F-FES) positron-emission tomography/computed tomography (PET/CT) may permit accurate reevaluation of estrogen receptor status in recurrent or metastatic breast cancer when repeat...
Sumanta K. Pal, MD: Let's Get More Patients With Rare Tumors Into Clinical Trials
Sumanta K. Pal, MD, of City of Hope, talks about the need for investigators across the country to enroll their patients with rare tumors in clinical trials. He describes a trial he is leading for papillary kidney cancer and how others can join his efforts.
Karim Fizazi, MD, PhD: We Need to Find a Way to Make Cancer Drugs Affordable
Karim Fizazi, MD, PhD, of Gustave Roussy, urges governments, insurers, and pharmaceutical companies to work together in order to find a way to make anticancer drugs affordable and accessible for all patients.
FDA Pipeline: Assay Approval, Breakthrough Designations for AI Technology and CLL, and More
In the past week, the U.S. Food and Drug Administration (FDA) approved a companion diagnostic assay, granted Breakthrough Device and Breakthrough Therapy designations, and extended the review period of a proposed treatment. The agency also published four draft guidances and one final guidance...
Incidence of Nonmelanoma Skin Cancer in Recipients of Multiple Kidney Transplants
The incidence of nonmelanoma skin cancer may be more common in recipients of kidney transplants vs patients on maintenance dialysis. Researchers looked to determine if the risk of nonmelanoma skin cancer is lower during periods of graft loss with a return to dialysis vs during periods of...
Does Postoperative Conformal Radiotherapy Improve Survival in Pediatric Patients With Ependymoma?
Treatment with conformal radiation therapy immediately following surgery in children with ependymoma may greatly improve survival. The findings were published by Merchant et al in the Journal of Clinical Oncology. “Historically, children under the age of 3 with ependymoma have a worse...
Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Gulley et al found that PROSTVAC, a viral vector-based immunotherapy, did not improve overall survival or 6-month event-free survival vs placebo in patients with asymptomatic or minimally symptomatic metastatic castration-resistant...
Activity of Cabozantinib in Advanced Non–Clear Cell Renal Cell Carcinoma
In a retrospective cohort study reported in The Lancet Oncology, Chanzá et al found evidence of activity of cabozantinib in advanced non–clear cell renal carcinoma. Cabozantinib is approved in metastatic renal cell carcinoma on the basis of studies in clear cell histology. As noted by ...
What Is the Best Field-Directed Treatment for Actinic Keratosis?
In a Dutch study reported in The New England Journal of Medicine, Jansen et al found that 5% fluorouracil cream was the best of four field-directed treatments for actinic keratosis, the most common premalignant skin disease in the white population. Study Details The study examined the...
Perceived Infertility Risk and Actual Fertility Status in Adult Survivors of Childhood Cancer
In a report from the St. Jude Lifetime Cohort Study in the Journal of Clinical Oncology, Lehmann et al found that perceptions of risk of infertility were often discordant with laboratory-assessed fertility status in adult survivors of childhood cancer. Study Details In the study, 1,067 survivors...
Addition of Pegylated Recombinant Human Hyaluronidase to FOLFIRINOX in Metastatic Pancreatic Adenocarcinoma
In the phase I/II SWOG S1313 trial, which was reported in the Journal of Clinical Oncology by Ramanathan et al, researchers found that the addition of pegylated recombinant human hyaluronidase (PEGPH20) to modified (m) FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) worsened...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation proudly recognize the winners of ASCO’s Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO...
Statement on White House’s FY2020 Budget Proposal by ASCO President Monica M. Bertagnolli, MD, FACS, FASCO
ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, issued the following statement earlier this week: We strongly oppose the White House budget proposal for fiscal year (FY) 2020, which would stall our nation's progress against cancer and impede access to needed care for the millions of...
2019 Thoracic Cancers Symposium: Trends in Use of Prophylactic Cranial Irradiation for Extensive-Stage SCLC
A new survey of radiation oncologists points to a sharp decline in the use of prophylactic cranial irradiation for patients with extensive-stage small cell lung cancer (SCLC), indicating a rapid change in standard practice for the disease following the 2017 publication of a major clinical trial by...
2019 Thoracic Cancers Symposium: Effect of Structured Patient Exposure to the NCCN Guidelines for NSCLC
A new clinical trial found that exposing patients to tailored versions of the National Comprehensive Cancer Network (NCCN®) Guidelines for non–small cell lung cancer (NSCLC) may help drive smoking cessation, testing for potential biomarkers and, for early-stage disease, more...
2019 Thoracic Cancers Symposium: Local Consolidative Therapy and Overall Survival in Oligometastatic NSCLC
A new analysis of patients treated with local consolidative therapy for oligometastatic non–small cell lung cancer (NSCLC) found that the intensive treatment approach is associated with improved overall survival. Local consolidative therapy—consisting of radiation therapy or...
Nivolumab Plus Ipilimumab in Advanced NSCLC: Outcomes by PD-L1 and Tumor Mutational Burden Status
As reported in the Journal of Clinical Oncology by Ready et al, the phase II CheckMate 568 trial has shown that higher tumor mutational burden is associated with response, irrespective of programmed cell death ligand 1 (PD-L1) expression in first-line nivolumab plus low-dose ipilimumab treatment of ...
HHS Secretary Appoints Norman E. Sharpless, MD, as FDA Acting Commissioner
Today, the Secretary of Health and Human Services (HHS) Alex M. Azar II appointed Norman E. Sharpless, MD, to be the acting Commissioner of the U.S. Food and Drug Administration (FDA). He will be replacing the current FDA Commissioner, Scott Gottlieb, MD, who announced his resignation on March 5....
Addition of Preoperative Breast MRI to Standard Evaluation in Local Ductal Carcinoma in Situ
In a French phase III trial reported in the Journal of Clinical Oncology, Balleyguier et al found that the addition of breast magnetic resonance imaging (MRI) to standard radiologic evaluation did not improve surgical reintervention rates in women with ductal carcinoma in situ undergoing...
FDA Approves Trastuzumab-qyyp in HER2-Overexpressing Breast and Gastric Cancers
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-qyyp (Trazimera), a biosimilar to trastuzumab (Herceptin), for the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal...
Lack of Genetic Diversity in Common Cancer Cell Lines
Researchers have found that some commercial cancer cell lines used for laboratory studies have mislabeled ancestry when it comes to minorities. These findings were published by Hooker et al in Cancer Epidemiology, Biomarkers & Prevention. “A lack of diversity is prevalent in every level...
Global Incidence of Undiagnosed Pediatric Cancers
Nearly half of all childhood cancers are not being diagnosed globally, according to a new modeling study published by Ward et al in The Lancet Oncology. “Our model suggests that nearly one in two children with cancer are never diagnosed and may die untreated,” said lead...
Intense Neoadjuvant Androgen Deprivation Before Prostatectomy in Locally Advanced Prostate Cancer
In a phase II trial reported in the Journal of Clinical Oncology, McKay et al found a trend toward improved pathologic response or minimal residual disease with the addition of neoadjuvant abiraterone and prednisone to enzalutamide and leuprolide prior to radical prostatectomy in patients with...
Subsequent Primary Neoplasms in Survivors of Adolescent and Young Adult Cancers
In a UK population-based cohort study (Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Bright et al found that subsequent primary neoplasms were most common in survivors of adolescent and young adult (AYA) breast, cervical, and testicular cancers, as well as Hodgkin...
Safety Comparison of Two Dosing Regimens for Nivolumab Plus Ipilimumab in Advanced Melanoma
In the phase IIIb/IV CheckMate 511 study reported by Lebbé et al in the Journal of Clinical Oncology, a regimen of nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg (NIVO3+IPI1) was found to significantly reduce the incidence of treatment-related grade 3 to 5 adverse events compared with...
Humanitarian, Cancer Specialist Advocates for Universal Access to Care as a Basic Human Right
There is a plethora of educational books for patients with cancer and their families; advocates and patients themselves write most. Books in this genre often have a difficult time distilling the hard science of oncology into a lay-friendly narrative that keeps the reader engaged from cover to...
Conservatively Managing Ovarian Tumors
In an interim analysis of a prospective cohort study (IOTA5) reported in The Lancet Oncology, Wouter Froyman, MD, and colleagues found that the risk of malignancy and acute complications is low when adnexal masses with benign ultrasound findings are managed conservatively. In the study, patients...
Factors Influencing Conversion to Mastectomy in Ductal Carcinoma in Situ
In a prospective cohort clinical trial reported in JAMA Oncology, Constance D. Lehman, MD, PhD, and colleagues found that multiple factors, including magnetic resonance imaging (MRI) findings, played a role in conversion to mastectomy among women with ductal carcinoma in situ (DCIS) who were...
We Need Better Screening Methods for Detecting Breast Cancer
MY BREAST CANCER was probably a decade in the making, although I only became aware that there might be a problem in 2014, when I noticed some slight pain in my left breast. A routine mammogram and ultrasound found benign cysts in my dense breasts, which most likely explained the pain, I was told,...
Update on Newer Treatments in Non-Hodgkin Lymphomas
AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas (NHLs), including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), ...
FDA Approves Trifluridine/Tipiracil for Recurrent, Metastatic Gastric and GEJ Adenocarcinoma
ON FEBRUARY 22, the U.S. Food and Drug Administration approved trifluridine/tipiracil tablets (Lonsurf)—a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor—for adult patients with metastatic gastric or gastroesophageal junction...
FDA Grants Accelerated Approval to Atezolizumab/Nab-Paclitaxel; Regular Approval Contingent on Confirmatory Trials
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) plus nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) for the treatment of adults with unresectable, locally advanced or metastatic, programmed cell death ligand 1 (PD-L1)-positive ...
Omega-3 Fatty Acids
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, explore the use of omega-3 fatty acids, which have...
A Peaceful Transformation: The Origin of the Frederick National Laboratory
JUST 2 MONTHS before Congress passed what to this day is America’s most sweeping anticancer legislation, President Richard Nixon came to Fort Detrick in Frederick, Maryland, to declare his administration’s historic commitment to the fight. “I have come here today for the purpose of making an...
Roy L. Silverstein, MD, Begins Term as 2019 ASH President
ROY L. SILVERSTEIN, MD, an expert in platelet and vascular cell biology, as well as clinical nonmalignant hematology and thrombosis, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2019. Dr. Silverstein is Chairman of the Department of...
Health-Care Fraud Prosecutions Are on the Rise
Prosecuting health-care fraud is a top priority for the U.S. Department of Justice (DOJ) and other federal government agencies.1,2 After all, the government earns a $6 return for every $1 that it spends on enforcement. In December 2018, the DOJ announced that it had obtained more than $2.5 billion...
Cabozantinib for Hepatocellular Carcinoma Previously Treated With Sorafenib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 14, 2019, cabozantinib was approved for the...
Reshaping the Treatment Landscape in Refractory Multiple Myeloma
THE TREATMENT approaches for multiple myeloma, both newly diagnosed and relapsed disease, continue to undergo major transformation as new agents and combinations are being introduced.1 This change has been driven by the introduction of novel drug classes such as monoclonal antibodies, as well as...
Addition of Elotuzumab to Pomalidomide and Dexamethasone in Previously Treated Patients With Multiple Myeloma
AS REPORTED in The New England Journal of Medicine by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase II ELOQUENT-3 trial has shown that the addition of elotuzumab to pomalidomide and dexamethasone significantly prolonged...
ASH President Roy Silverstein, MD, Issues Comment on Maintenance of Certification Recommendations Draft
RECENTLY, THE American Society of Hematology (ASH) submitted feedback on draft recommendations for reforming Maintenance of Certification (MOC) to a commission appointed by the American Board of Medical Specialties (ABMS) and other entities. The “Vision Commission” released a report of its draft...
Although Evidence Is Clear That Lung Cancer Screening Saves Lives, Adoption Rates Remain Low
The findings of the National Lung Screening Trial (NLST), reported in 2011, revealed that participants who received low-dose helical computed tomography (CT) scans had a 20% lower risk of dying of lung cancer than participants who received standard chest x-rays. Despite these results,...
Robin Zon, MD, FACP, FASCO, Elected President of Michiana Hematology Oncology
MICHIANA HEMATOLOGY Oncology has announced that Robin Zon, MD, FACP, FASCO, has been elected President by its shareholders. In her new role as President, Dr. Zon will oversee and maintain leadership of the practice. Dr. Zon is a member of ASCO and was awarded Fellow status; with ASCO, she served...
Michael Cabana, MD, MA, MPH, and Lori Pbert, PhD, Join USPSTF
THE U.S. PREVENTIVE Services Task Force (Task Force) announced the addition of two new members: Michael Cabana, MD, MA, MPH, and Lori Pbert, PhD. Both were appointed to serve 4-year terms, which began in January 2019. Dr. Cabana is Professor of Pediatrics, Epidemiology, and Biostatistics and a...
Position Paper Addresses Shortages of Chemotherapy and Supportive Care Agents for Pediatric Oncology Patients
Shortages of essential chemotherapy drugs for children undergoing cancer treatment have been an increasingly frequent obstacle for patients and hospitals in the United States. These shortages can result in increased medication errors, delayed administration of life-saving therapy, inferior...
New Patient Resource: NCCN Guidelines for Patients With Squamous Cell Skin Cancer
The National Comprehensive Cancer Network® (NCCN) has published a new book of patient information that explains prevention, diagnosis, and treatment for squamous cell skin cancer. Squamous cell and basal cell skin cancers are responsible for about 5 million annual incidents of nonmelanoma...
Patients With Breast Cancer Provide Recommendations to Ease Financial Toxicity
A qualitative study yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services, and financial assistance to reduce long-term, breast cancer–related economic burden. The study was published by Dean et al in Cancer. Unique...
Modeling Study of Scaled-up HPV Vaccination and Cervical Cancer Screening
In a modeling study reported in The Lancet Oncology, Simms et al detailed the preventive effects on cervical cancer that could be achieved by scaled-up human papillomavirus (HPV) vaccination and cervical screening efforts with the aim of disease elimination. The major modeling projections are...
Combining Tumor Budding and Lymphocytic Infiltration May Improve Prognostic Accuracy in Colorectal Cancer
A study evaluating a prognostic signature derived from integrating tumor budding, lymphocyte infiltration, and their spatial relationship has found that the method could more accurately stratify patients with stage II colorectal cancer at high risk for disease-specific death compared with...
